PCSK9 and hypothyroidism: In the replication dataset, there was a trend towards an increased risk of hypothyroidism for genetically proxied inhibition of HMGCR (OR, 1.008 per 1-mmol/L lower in LDL-C; 95% CI 1.001 to 1.014; P = 0.019) and a trend in a decreased risk of hypothyroidism for genetically proxied inhibition PCSK9 (OR, 0.995; 95% CI 0.990 to 1.000; P = 0.031).